Oncopeptides AB Company Description

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.

Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients.

The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors.

Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

Oncopeptides AB (publ)

Country	Sweden
Founded	2000
Industry	Biological Products, Except Diagnostic Substances
Employees	57
CEO	Sofia Heigis

Contact Details

Address: Luntmakargatan 46 Stockholm, 111 37 Sweden
Phone	46 86 15 20 40
Website	oncopeptides.com

Stock Details

Ticker Symbol	0RN4
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Sofia Heigis	Chief Executive Officer
Henrik Bergentoft	Chief Financial Officer
Eva Nordström	Chief Operating Officer
David Augustsson	Head of Investor Relations